These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9872687)

  • 1. Using multiple pharmacoeconomic methods to conduct a cost-effectiveness analysis of histamine H2-receptor antagonists.
    McCoy S; Blayney-Chandramouli J; Mutnick A
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S8-12. PubMed ID: 9872687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals.
    Segal R; Oh T; Ben-Joseph R; Russell WL
    Hosp Formul; 1994 May; 29(5):379-82, 388-91. PubMed ID: 10136601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level.
    Ohsawa T; Hirata W; Higichi S
    Int J Clin Pharmacol Res; 2002; 22(2):29-35. PubMed ID: 12503773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic-interchange program for oral histamine H2-receptor antagonists.
    Chase SL; Peterson AM; Wordell CJ
    Am J Health Syst Pharm; 1998 Jul; 55(13):1382-6. PubMed ID: 9659966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Criteria-based DUE aids in selection of preferred agent.
    Drea EJ
    Hosp Formul; 1991 Nov; 26 Suppl D():25-7. PubMed ID: 10136562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-effectiveness analysis of stress ulcer prophylaxis.
    Schupp KN; Schrand LM; Mutnick AH
    Ann Pharmacother; 2003 May; 37(5):631-5. PubMed ID: 12708935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategy for developing a safe and cost-effective H2-receptor antagonist program.
    Quercia RA; Chow MS; Jay GT; Quintiliani R
    Hosp Formul; 1991 Nov; 26 Suppl D():20-4. PubMed ID: 10136561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
    Slichenmyer WJ; Donehower RC; Chen TL; Bowling MK; McGuire WP; Rowinsky EK
    Cancer Chemother Pharmacol; 1995; 36(3):227-32. PubMed ID: 7781143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and acid-suppressant properties of histamine2-receptor antagonists for the prevention of stress-related mucosal damage in critical care patients.
    Schentag JJ; Carter CA; Welage LS
    DICP; 1989 Oct; 23(10 Suppl):S36-9. PubMed ID: 2573208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National survey of stress ulcer prophylaxis.
    Lam NP; Lê PD; Crawford SY; Patel S
    Crit Care Med; 1999 Jan; 27(1):98-103. PubMed ID: 9934901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer].
    Belousov IuB; Karpov OI; Belousov DIu; Beketov AS
    Ter Arkh; 2007; 79(2):58-66. PubMed ID: 17460971
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of histamine receptor-2 antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients*.
    MacLaren R; Campbell J
    Crit Care Med; 2014 Apr; 42(4):809-15. PubMed ID: 24365863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.
    Langtry HD; Grant SM; Goa KL
    Drugs; 1989 Oct; 38(4):551-90. PubMed ID: 2573505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching the histamine H2 receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation.
    Tasch RF; Goeree R; Henke CJ; O'Brien BJ
    Pharmacoeconomics; 1996 Jan; 9(1):61-75. PubMed ID: 10160088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What are the differences between the H2-receptor antagonists?
    Schunack W
    Aliment Pharmacol Ther; 1987; 1 Suppl 1():493S-503S. PubMed ID: 2908767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of histamine H2 receptor blockers on reparative processes in the gastric mucosa of patients with gastric peptic ulcer].
    Alekseenko SA; Timoshin SS
    Ter Arkh; 1999; 71(2):23-6. PubMed ID: 10222548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shifting physician prescribing to a preferred histamine-2-receptor antagonist. Effects of a multifactorial intervention in a mixed-model health maintenance organization.
    Brufsky JW; Ross-Degnan D; Calabrese D; Gao X; Soumerai SB
    Med Care; 1998 Mar; 36(3):321-32. PubMed ID: 9520957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in prescribing patterns of intravenous histamine2-receptor antagonists results in significant cost savings without adversely affecting patient care.
    Fudge KA; Moore KA; Schneider DN; Sherrin TP; Wellman GS
    Ann Pharmacother; 1993 Feb; 27(2):232-7. PubMed ID: 8094986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of famotidine with cimetidine and ranitidine.
    Berardi RR; Tankanow RM; Nostrant TT
    Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do H2 receptor antagonists have a therapeutic role in childhood?
    Kelly DA
    J Pediatr Gastroenterol Nutr; 1994 Oct; 19(3):270-6. PubMed ID: 7815256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.